These studies providing mechanistic insights into the up-regulation of the PRLR by its endogenous cognate hormone and receptor indicate the relevance of their participation in resistance to adjuvant therapies and further the basis for the treatment of refractory states in ERα+ breast cancers. The gene discussed is ESR1; the disease is breast cancer.